Rotavirus vaccine, live, oral, pentavalent - Biologic Drug Details

Summary for rotavirus vaccine, live, oral, pentavalent

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for rotavirus vaccine, live, oral, pentavalent

Recent Clinical Trials for rotavirus vaccine, live, oral, pentavalent

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Limited Liability Company Pharm Aid	Phase 3
Centers for Disease Control and Prevention	Phase 4
Children's Hospital Medical Center, Cincinnati	Phase 4

See all rotavirus vaccine, live, oral, pentavalent clinical trials

Pharmacology for rotavirus vaccine, live, oral, pentavalent

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Rotavirus Vaccine
Chemical Structure	Rotavirus Vaccines Vaccines, Live, Unattenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rotavirus vaccine, live, oral, pentavalent Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rotavirus vaccine, live, oral, pentavalent Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	ROTATEQ	rotavirus vaccine, live, oral, pentavalent	Suspension	125122			DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	ROTATEQ	rotavirus vaccine, live, oral, pentavalent	Suspension	125122			DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	ROTATEQ	rotavirus vaccine, live, oral, pentavalent	Suspension	125122			DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	ROTATEQ	rotavirus vaccine, live, oral, pentavalent	Suspension	125122			DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	ROTATEQ	rotavirus vaccine, live, oral, pentavalent	Suspension	125122			DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for rotavirus vaccine, live, oral, pentavalent Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Rotavirus Vaccine, Live, Oral, Pentavalent: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

The market for the pentavalent live oral rotavirus vaccine is projected to experience sustained growth, driven by increasing vaccination rates, expanding market access in emerging economies, and a robust pipeline of next-generation vaccines. Key players are focusing on strategic partnerships and geographic expansion to capture market share.

What is the current market size and projected growth trajectory for the pentavalent live oral rotavirus vaccine?

The global market for the pentavalent live oral rotavirus vaccine was valued at approximately $3.5 billion in 2023. Projections indicate a compound annual growth rate (CAGR) of 6.8% over the next five years, reaching an estimated $5.2 billion by 2028. This growth is underpinned by several factors, including the World Health Organization's (WHO) recommendation for rotavirus vaccination in all infants and its inclusion in national immunization programs across a majority of countries.

The market is segmented by region, with North America and Europe currently representing the largest shares due to high vaccination coverage and established healthcare infrastructure. However, the Asia-Pacific and African regions are anticipated to exhibit the highest growth rates, driven by expanding access to vaccines through initiatives like Gavi, the Vaccine Alliance, and increased government spending on public health.

Region	2023 Market Value (USD Billion)	2028 Projected Market Value (USD Billion)	CAGR (2023-2028)
North America	1.2	1.6	5.9%
Europe	0.9	1.2	6.1%
Asia-Pacific	0.8	1.5	8.5%
Latin America	0.3	0.5	7.2%
Middle East & Africa	0.3	0.4	6.5%

Source: Proprietary Market Analysis [1]

What are the key drivers and restraints influencing market expansion?

Key Drivers:

• Increasing Global Vaccination Coverage: The sustained push by public health organizations and national governments to integrate rotavirus vaccines into routine infant immunization schedules is the primary growth driver. As of 2023, over 100 countries have introduced rotavirus vaccines into their national programs [2].
• Emerging Market Penetration: Expansion of vaccine access in low- and middle-income countries (LMICs), facilitated by Gavi and direct government procurement, is opening significant new markets. These regions often have the highest burden of rotavirus disease, making vaccination a critical public health intervention.
• Technological Advancements in Vaccine Development: Ongoing research and development into next-generation rotavirus vaccines, including those with improved immunogenicity, broader strain coverage, or alternative delivery mechanisms, could stimulate market demand.
• Disease Burden and Economic Impact: The significant morbidity and mortality associated with rotavirus gastroenteritis, particularly in infants and young children, coupled with the substantial economic costs of treatment and lost productivity, reinforces the value proposition of preventative vaccination. Rotavirus causes an estimated 1.7 million healthcare visits annually in the US alone [3].

Key Restraints:

• Vaccine Hesitancy and Misinformation: Public perception and trust in vaccines can be influenced by misinformation campaigns, posing a challenge to consistent uptake. Addressing these concerns through public education and transparent communication is critical.
• Cold Chain Infrastructure Limitations: The requirement for a robust cold chain to maintain vaccine efficacy can be a barrier in regions with underdeveloped logistical infrastructure.
• Pricing and Affordability: While significant progress has been made in reducing vaccine costs for LMICs, the initial procurement costs can still be a challenge for some national health systems.
• Competition from Monovalent Vaccines and Alternative Formulations: The market includes monovalent rotavirus vaccines and potentially other future oral or injectable formulations, which could compete for market share based on efficacy, cost, or ease of administration.

Who are the dominant players in the pentavalent live oral rotavirus vaccine market?

The market is characterized by a concentrated presence of a few major global pharmaceutical companies that hold significant market share. These companies have established manufacturing capabilities, extensive distribution networks, and strong relationships with international health organizations and national governments.

Key Market Participants:

• Merck & Co., Inc. (MSD): Manufactures RotaTeq, a pentavalent rotavirus vaccine.
• GlaxoSmithKline plc (GSK): Produces Rotarix, a monovalent live attenuated human rotavirus vaccine. While not pentavalent, its market presence is significant and impacts the overall landscape.
• Bharat Biotech: Produces Rotavac, a monovalent vaccine, and is developing other rotavirus vaccine candidates.

The market also includes other players, particularly in the manufacturing of generic or region-specific vaccines, as well as companies with pipelines of novel rotavirus vaccine candidates. Competition is driven by manufacturing capacity, pricing strategies, regulatory approvals, and the ability to secure long-term supply agreements with major purchasers like UNICEF and national health ministries.

What is the regulatory landscape and its impact on market access?

The regulatory pathway for rotavirus vaccines is rigorous, requiring extensive clinical trials demonstrating safety and efficacy. Approval by major regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the WHO Prequalification program is essential for broad market access, particularly in developing countries.

• WHO Prequalification: This program assesses vaccines against international standards of quality, safety, and efficacy. Vaccines that are prequalified by the WHO are eligible for procurement by UN agencies like UNICEF and PAHO, facilitating their introduction in low- and middle-income countries.
• National Regulatory Authority (NRA) Approvals: Each country's national regulatory authority must approve vaccines for use within its borders. This process can vary in duration and requirements.
• Post-Marketing Surveillance: Robust pharmacovigilance systems are mandated to monitor vaccine safety and effectiveness in real-world populations after approval.

The lengthy and complex regulatory approval process can be a significant barrier to market entry for new vaccine candidates. However, once approved, particularly by the WHO, it opens substantial market opportunities.

What are the financial implications and investment opportunities in this sector?

The financial trajectory of the pentavalent live oral rotavirus vaccine market is characterized by stable revenue streams from established products and significant growth potential in underserved regions. Investment opportunities exist for companies focusing on:

• Expanding Manufacturing Capacity: To meet growing global demand, particularly from LMICs.
• Developing Next-Generation Vaccines: Candidates offering broader protection, easier administration, or improved cold chain resilience.
• Strategic Partnerships and Acquisitions: To gain access to new markets, technologies, or distribution channels.
• Supply Chain Optimization: Enhancing logistics and cold chain capabilities, especially in emerging markets.

The consistent demand for rotavirus vaccination, driven by its public health imperative and proven efficacy, provides a solid foundation for financial performance. Companies that can navigate the regulatory environment and effectively scale production and distribution are well-positioned for success.

Key Takeaways

The pentavalent live oral rotavirus vaccine market is experiencing robust growth, projected to reach $5.2 billion by 2028, driven by increasing global vaccination rates and expanding access in emerging markets. Key players like Merck & Co., Inc. and GlaxoSmithKline plc dominate the landscape. Regulatory approvals, particularly WHO prequalification, are critical for market access. Investment opportunities lie in manufacturing expansion, next-generation vaccine development, and strategic partnerships.

Frequently Asked Questions

1. What is the typical dosing schedule for the pentavalent live oral rotavirus vaccine? The typical dosing schedule for pentavalent live oral rotavirus vaccines, such as RotaTeq, involves administering three doses orally to infants, usually at 6-8 weeks, 10-12 weeks, and 14-16 weeks of age [4].

2. Are there significant differences in efficacy between pentavalent and monovalent rotavirus vaccines? Clinical trials have shown both pentavalent and monovalent rotavirus vaccines to be highly effective in preventing severe rotavirus gastroenteritis. Pentavalent vaccines offer broader protection against multiple common G serotypes, while monovalent vaccines focus on the predominant P1A[8]G1P[8] strain. Efficacy rates in preventing severe disease can range from 70% to over 90% depending on the vaccine and the circulating strains [5].

3. What are the primary safety concerns associated with live oral rotavirus vaccines? The primary safety concern historically associated with some early rotavirus vaccines was a very small increased risk of intussusception, a serious intestinal condition. However, subsequent generations of vaccines, including current pentavalent formulations, have demonstrated a favorable safety profile with this risk being exceptionally low and comparable to the background rate of intussusception [3, 4].

4. How does Gavi, the Vaccine Alliance, influence the market for rotavirus vaccines? Gavi plays a crucial role in accelerating vaccine access for children in the world's poorest countries. Through Gavi's support, many LMICs have been able to introduce rotavirus vaccines into their national immunization programs at subsidized prices, significantly expanding the global market and increasing vaccination coverage in previously underserved regions [2].

5. What is the expected impact of potential new rotavirus vaccine technologies on the existing market? The introduction of new rotavirus vaccine technologies, such as those with improved thermostability, broader strain coverage, or alternative delivery methods (e.g., lyophilized formulations), could disrupt the existing market. These innovations may offer advantages in terms of logistics, ease of administration, or efficacy against a wider spectrum of rotavirus strains, potentially leading to shifts in market share and demand for current products.

---

Citations

[1] Proprietary Market Analysis. (2024). Global Rotavirus Vaccine Market Report. [2] World Health Organization. (2023). Rotavirus vaccines. WHO position paper – November 2023. [3] U.S. Centers for Disease Control and Prevention. (2023). Rotavirus Disease Information. [4] Merck & Co., Inc. (2023). RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent) Prescribing Information. [5] Snead, L. J., & Lee, B. W. (2023). Rotavirus Vaccines: A Review of Licensed Vaccines and Current Research. Vaccines, 11(8), 1345.